Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine bromide for post-COVID fatigue
RBR-107j3g4vPhase 3Completed
- Sponsor
- Universidade Federal Fluminense
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pyridostigmine in post-viral fatigue syndrome (PVFS) and post-COVID syndrome (2 arms), sponsored by Universidade Federal Fluminense. Primary endpoint: Fatigue assessment. Started Aug 2022; status: completed.
02
Drugs
pyridostigmine
03
Conditions
post-viral fatigue syndrome (PVFS)post-COVID syndrome
Beyond the preview
Go deeper on RBR-107j3g4v.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-107j3g4v.